Objective: To investigate the role of HIV-1 envelope subtypes on disease progression in a rural cohort of Ugandan adults where two major HIV-1 subtypes (A and D) exist.
Introduction
The rate of HIV-1 disease progression varies widely between infected individuals, but the factors responsible for this are not well understood. This variation has been partly explained by the phenotype of the virus, with some reports suggesting a more rapid progression to AIDS in patients with fast-replicating syncytium inducing (SI) viruses [1, 2] . A deletion allele of CCR5 co-receptor gene has also been reported to slow disease progression in heterozygotes compared with individuals homozygous for the normal CCR5 gene [3] . Surpris-ingly, the levels of chemokine that bind this receptor do not vary signi®cantly between rapid and slow progressors [4] . The age at seroconversion has also been shown to in¯uence disease progression [5] . The role of host HLA genetic variation in relation to disease progression has been controversial, with some studies showing an association and others failing to demonstrate this (for a review see [6] ).
So far, 11 different HIV-1 subtypes (A±K) have been identi®ed within the major group M, and more distant or outlier viruses, classi®ed as group O have been reported mainly from Central and West Africa [7] . Another group N composed of highly divergent strains has also been reported [8] . These subtypes have been identi®ed by comparisons of nucleotide sequences in different parts of the HIV-1 genome, especially the env and gag regions. Recombinant viruses which belong to two distinct subtypes in different regions of the genome are also increasingly being recognized, and it is estimated that around 20% of the current strains in the pandemic are recombinants (for a review see [9] ). Some of these recombinant HIV-1 are unique and more prevalent in particular geographical regions, and these have been designated as`circulating recombinant forms' or CRF [7] . Members of a CRF resemble each other over the entire genome with similar breakpoints reecting common ancestry. Such CRF include A/E prevalent in Thailand, A/G common in west Africa , A/G/I identi®ed in Cyprus and Greece and recently A/G/J described in patients from Burkina Faso and Mali (for a review see [9] ). These CRF have not been reported in East Africa [10] nor in our study area [11] .
Very little information exists on the relevance of these subtypes to disease progression. In one study, the rates of disease progression evaluated by the decline in CD4 lymphocyte count were similar between groups of Ethiopian immigrants carrying HIV-1 subtype C and non-Ethiopian Israelis infected with subtype B [12] . However, this study compared two groups on antiretroviral therapy with different demographic composition, mode of transmission, and host genetics. Another study in Senegal reported that individuals infected with HIV subtype A were found to progress clinically more slowly than those infected with non-A subtypes [13] . In their study women infected with a non-A subtype were eight times more likely to develop AIDS than were those infected with subtype A. A study in London reported that differences in disease progression to AIDS and death and CD4 lymphocyte count decline between HIV-1 infected Africans and non-Africans could not be attributed to ethnicity and viral subtypes [14] ; however, the Africans were infected with diverse subtypes. A similar rate of disease progression was reported among individuals infected with HIV-1 genetic subtypes A±D [15] . The problem with this study was that the time of seroconversion was not known and it was based on small numbers. Recently, another study in Thailand has reported that HIV-1 subtypes B9 and E were associated with similar degrees of immunosuppresion and opportunistic infection patterns [16] among a group of HIV-1 infected individuals; however, these were AIDS patients in hospitals.
In this study, we have investigated the role of HIV-1 genetic subtype on disease progression as measured by: the rate of CD4 lymphocyte count decline; progression to death; progression to AIDS (stage 4) or death; to the ®rst CD4 count , 200 3 10 6 cells/l; and to stage 3 or 4 or death in an HIV-1 natural history cohort in rural Uganda where two major HIV-1 subtypes (A and D) exist. The majority of the subjects had estimated dates of seroconversion. In this population adult HIV-1 infection is acquired almost exclusively by heterosexual transmission [17] and antiretroviral drugs are not yet available. For this study the envelope subtype was considered based on envelope HMA and V3 sequence data. We decided to determine subtype in the cohort using the env (V3 env) region because of its association with pathogenesis and host immunity [18] .
Subjects and methods
Subjects and sample collection An HIV-1 natural history cohort (NHC) was established in 1990 in rural SW Uganda [19] ; recruits are from a large population study where the dynamics of HIV infection are examined by annual bleeds of the population to test for HIV status. The NHC includes seroprevalent cases of HIV-1 infection detected during the initial survey round of the population study in 1989/1990 [20] and seroincident cases who had an initial negative test followed by a positive test during the annual serosurveys. All participants in the cohort are invited to attend the study clinic every 3 months and provide a detailed medical history, and undergo a full physical examination and laboratory investigation. They also attend for investigations and treatment if ill at other times.
Clinical follow-up
Participants are staged at each routine visit using the proposed World Health Organization (WHO) staging system [21] using a computer algorithm. WHO stage 4 is equivalent to AIDS. CD4 lymphocyte counts were determined every 6 months using FACSCOUNT (Becton Dickinson International, Denderstraat 24, Belgium). Compliance at routine visits is good with . 90% of patients being seen at least once a year. Deaths in cohort participants are reported by local home visitors, and even if a person has moved and not been seen for several years, information about deaths comes from family residing in the study area. Death status was unknown for only three participants at the end of 1998, and their follow-up to death was censored at the end of the last year they were known to be alive. For this study, the period of observation is from 1990 to1998.
Subtype analysis
Participants seen between December 1995 and December 1998 had their blood collected in EDTA tubes. These blood samples were transferred to Uganda Virus Research Institute (UVRI), Entebbe within 24 h and frozen at À208C prior to DNA extraction. DNA was extracted from frozen whole blood using either the commercial Puregene Kit (Gentra Systems Inc., North Carolina, USA) or based on a previously described method [11] .
HMA subtyping analysis was carried out at UVRI according to standard procedures [22] . In most cases the primer pairs used were ED5/ED12 for the ®rst round and ED31/ED33 for the second round generating a fragment of 0.5 kb spanning the C2±C3 regions and which includes the V3 env region. For samples that were untypable by HMA (n 36), an aliquot of HMA second round products or unampli®ed DNA was sent to the Centre for HIV Research, Edinburgh for sequencing as described previously [23] .
Statistical methods

CD4 lymphocyte counts
The two-level random effects model is a multiple regression model that recognizes that the data are series of CD4 lymphocyte counts from the same individuals over time, and allows each participant to have their own estimated intercept and rate of decline by introducing participant-speci®c elements (random effects). We used a square root transformation of absolute CD4 lymphocyte counts which has an approximately linear decline and stable variance over time [24, 25] . The statistical package MLn [26] was used to estimate and compare the mean rates of square root CD4 lymphocyte count decline in participants with HIV-1 subtype A and D. The analyses were adjusted for age category (15±24, 25±34, 35±44 and > 45 years), sex and whether a prevalent or an incident case.
Clinical progression in the incident cases We calculated the individual survival times from the estimated date of seroconversion. We used Kaplan± Meier survival estimates of the proportion of individuals surviving, or remaining free from death, AIDS (stage 4) or death, the ®rst CD4 lymphocyte count , 200 3 10 6 /l, and stage 3 (or 4 or death). The participants' follow-up times were censored at the date last known to be alive for death and staging end points, and to their last CD4 lymphocyte count for CD4 , 200 3 10 6 /l. Cox's proportional hazards models were used to compare survival by subtype, adjusting for age category and sex. The analyses were performed using STATA version 6.0.
Results
Up to the end of 1998, 248 HIV-positive participants had been recruited into the NHC of whom 107 were prevalent and 141 were incident cases. The median time from last HIV-negative test to ®rst HIV-positive test for the incident cases was 1.02 years [interquartile range (IQR), 0.92±2.03] and the date of seroconversion was not known for prevalent cases but was before 1989. One hundred and sixty-four HIV-positive patients were successfully subtyped as A or D using the env region (128 by HMA and 36 by sequencing). The distribution of age at enrolment and sex of these participants by subtype is shown in Table 1 . The median age at enrolment (Table 2) The ratio of A : D subtypes was 1 : 1.24 [95% con®dence interval (CI), 1 : 2.28 to 1 : 0.70)] for prevalent cases and 1 : 1.68 (95% CI, 1 : 2.47 to 1 : 1.55) for incident cases. There was no evidence that these ratios were signi®cantly different (÷ 2 , 0.70; P 0.40).
The median follow-up time from ®rst to last CD4 lymphocyte count overall was 3.0 years (IQR, 1.7±3.9 years) and the follow-up times were comparable in There was no evidence of a signi®cantly modi®ed effect of subtype with age category (P 0.60), although this study has low power to detect such an effect. We have also repeated the analysis using CD4 lymphocyte counts from participants older than 25 years only. The results are similar to those for all ages: the estimated effect of subtype D compared to A on the rate of square root CD4 cell counts was À0.50 per year (95% CI, À1.15 to 0.14; P 0.13).
Clinical progression of incident cases infected with subtypes A and D The Kaplan±Meier survival curves from the estimated seroconversion date for the end-points death, and AIDS or death, are shown in Fig. 1 . The estimated cumulative survival probabilities for each endpoint at 4 years and 6 years from seroconversion are presented by subtype in Table 4 . Cumulative probabilities of survival are given because the median survival for the endpoints were not reached. There was a suggestion that for all end-points subtype A had a slower progression than subtype D, and this reached statistical signi®cance for the combined stage 3, stage 4 or death end-point.
Discussion
It has been suggested that viral genetics might have a role in HIV-1 disease progression [27] . Very little information exists regarding the relationship between HIV-1 subtypes and the natural history of infection, partly because there are few natural history cohorts in areas with diverse subtypes. The few reported studies have used individuals who were either on antiretroviral therapy, were not homogenous in terms of host genetic composition, mode of transmission or demographic composition, or their date of infection was not known [12, 14, 15] . The one other longitudinal study that looked at AIDS progression and HIV-1 subtypes compared subtype A with non-A subtypes, which were grouped together due to the limitation of numbers [13] . Our study has looked at 164 individuals infected with subtype A or D viruses in a Ugandan population. One hundred and seventeen of these had estimated dates of seroconversion, this being the largest study so far of its kind.
Although disease progression in our participants with subtypes A and D was not signi®cantly different for most end-points, there was a tendency for those with subtype D to progress faster than those with subtype A. For example, there was in excess of three times more deaths in those with subtype D than in those with subtype A. In their study [15] , Alaeus et al. also did not show a signi®cant difference in progression in individuals infected with subtypes A±D; however, there was a tendency for subtype D to progress faster than A: the mean CD4 lymphocyte count decline in D was twice that in A. Others have also reported slower progression in subtype A infections [13] . As suggested by others it is unlikely that a single characteristic such as subtype can account for signi®cant differences in disease progression [28] . However, an association of subtype with other factors such as phenotype in relation to disease progression needs to be explored.
In this study only patients with blood collected between December 1995 and December 1998 were included in the analysis. The exclusion of those who died before this time could be a potential source of bias; however, of the 141 incident cases enrolled by the end of December 1998, only six (4%) had died before December 1995.
Many studies have tried to establish the signi®cance of the HIV-1 subtype classi®cation in relationship to other properties such as immune recognition, co-receptor usage, transmission and other biological properties. Only a few studies have reported any relation between subtype and these properties. In Thailand, subtype E viruses have been shown to be associated with heterosexual transmission and subtype B with the homosexual mode of transmission [29] . A low frequency of subtype C with SI phenotype has also been reported in Ethiopian AIDS patients [30] , and CXCR4 co-receptor usage has been found to be rare among the C subtype isolates [31] .
Since CD4 lymphocyte count decline is a good measure of immunode®ciency and a determinant of progression to AIDS [32] , mean rates of decline in square root CD4 lymphocyte counts were used in addition to clinical progression. We have not used viral load as a measure of disease progression in this study. Viral load measurement kits are limited by the effect of HIV-1 viral diversity or subtypes on their sensitivity. In addition, most viral load kits amplify either gag or pol regions; in this study the envelope region was used and the 20% recombination reported in our cohort [11] would cause for substantial misclassi®cation.
It has been reported that the V3 env region is important in the pathogenesis of HIV-1 and it also plays a part in both cellular and humoral immunity [18] . This region also determines the viral phenotype and SI viruses are associated with more rapid progression of HIV-1 disease [2] . One report has suggested that subtype D viruses are associated with SI phenotype and are rapidly replicating,`rapid high' viruses [33] . If HIV-1 exerts its pathogenic effect through direct killing of CD4 lymphocytes, rapidly replicating subtype D viruses would be assumed to be associated with more rapid disease progression. However, this has not been shown convincingly.
Our study further shows that the rate of progression to AIDS in HIV-1 infected individuals is determined by a complex series of interactions between host and virus. Divergent patterns of progression to AIDS after infection from the same source [34] or subtype [35] have been reported and these might be explained by virus evolution and antiviral immune responses. Studies of this nature help with understanding the role of viral subtype in pathogenesis. This may be relevant to the dynamics and evolution of the HIV epidemic and will in¯uence vaccine development.
Currently two major HIV-1 subtype distribution patterns exist globally, the ®rst pattern is characterized by a stable epidemic with the same subtype proportions over time, as shown in our cohort studies and the second pattern as seen in Kalinningrad, in the former Soviet Union [36] is characterized by rapid introduction of new strains spreading the epidemic. Our results showing that env subtypes A-and D-infected patients do not differ signi®cantly in disease progression and death might partly contribute to the stable subtype epidemic seen in Uganda.
HIV is a complex virus with different regions that might have different roles in pathogenesis. For example, a number of cytotoxic T lymphocyte epitopes have been identi®ed the gag region. In addition, recombinant viruses are common in this and other populations [9, 11] . The association between subtypes and disease progression needs to be investigated using other HIV-1 viral regions before meaningful conclusions can be drawn; we are currently investigating this association using the gag regions.
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